Iovance Biotherapeutics Inc (IOVA)
Drugs • Health Care
July 30, 2026 Iovance Biotherapeutics Set to Share Q2 2026 Financial Results and Corporate Updates Iovance Biotherapeutics is set to announce its Q2 2026 financial results on August 6, with a conference call scheduled to discuss insights on TIL therapies and strategic updates. This event is crucial for stakeholders monitoring the company's advancements in cancer treatment.
July 17, 2026 Iovance Biotherapeutics Grants Inducement Stock Options to New Employees Iovance Biotherapeutics has granted stock options to 17 new employees to boost talent acquisition in cancer therapy development. The options come with a three-year vesting schedule, aligning employee interests with company goals.
June 19, 2026 Iovance Biotherapeutics Grants Inducement Stock Options to New Employees Iovance Biotherapeutics has granted inducement stock options to 27 new employees, aiming to attract talent and foster innovation in cancer therapies. The stock options, which vest over three years, align employee goals with the company's mission of advancing cancer treatment.
June 03, 2026 Iovance Biotherapeutics Achieves Milestone with Approval of Amtagvi® in Australia Iovance Biotherapeutics has achieved a milestone with the approval of Amtagvi® for advanced melanoma in Australia. This innovative therapy provides a new treatment option for patients who have not responded to previous therapies. The approval follows promising results from the C-144-01 clinical trial, highlighting the urgent need for effective melanoma treatments in Australia.
June 01, 2026 Iovance Biotherapeutics Secures FDA Approval for IOV-5001 IND Application Iovance Biotherapeutics has received FDA approval for its IND application for IOV-5001, a next-generation TIL therapy targeting aggressive cancers. The upcoming Phase 1/2 trial aims to enhance treatment efficacy while minimizing toxicity, offering hope for patients with limited options.
May 22, 2026 Iovance Biotherapeutics Announces Inducement Grants Under NASDAQ Listing Rules Iovance Biotherapeutics has approved inducement stock options for 13 new employees, aimed at attracting top talent in cancer therapy. The options, totaling 93,340 shares, will vest over three years, reflecting the company's commitment to innovation and workforce development in the biotech field.
May 21, 2026 Iovance Biotherapeutics Set to Showcase Innovations at Jefferies Global Healthcare Conference Iovance Biotherapeutics will showcase its advancements in tumor infiltrating lymphocyte therapies at the Jefferies Global Healthcare Conference. Key executives, including Interim CEO Dr. Fred Vogt, will discuss the company’s strategic vision and innovative treatments aimed at enhancing cancer care.
May 07, 2026 Iovance Biotherapeutics Reports Strong Q1 2026 Results and Strategic Advancements Iovance Biotherapeutics reported a 45% revenue increase in Q1 2026, driven by strong sales of Amtagvi. The company is expanding its treatment centers and anticipates continued growth in revenue, supported by an optimistic outlook and ongoing clinical trials.
April 27, 2026 Iovance Biotherapeutics to Announce Q1 2026 Financial Results and Corporate Developments Iovance Biotherapeutics will announce its Q1 2026 financial results on May 7, 2026. The conference call will provide crucial updates on their innovative TIL therapies and corporate strategies.
April 17, 2026 Iovance Biotherapeutics Expands Workforce with Inducement Grants Iovance Biotherapeutics has approved inducement stock options for twelve new employees as part of its strategy to strengthen its workforce and accelerate R&D in cancer therapies. The grants cover 135,470 shares with a vesting schedule designed to promote employee retention, reflecting the company's commitment to innovation in oncology.
March 20, 2026 Iovance Biotherapeutics Announces Inducement Stock Options Grant Iovance Biotherapeutics has issued inducement stock options for a new employee, covering 3,400 shares at an exercise price of $3.87. This move highlights the company's ongoing commitment to attracting top talent and advancing its innovative TIL therapies for cancer treatment.
February 26, 2026 Iovance Biotherapeutics Announces Conference Presentations Iovance Biotherapeutics will present at the TD Cowen and Barclays healthcare conferences, discussing advancements in tumor infiltrating lymphocyte therapies. The company aims to enhance cancer treatment through innovative approaches and personalized therapies.
February 24, 2026 Iovance Biotherapeutics Inc. Reports Positive Early Results in TIL Cell Therapy for Soft Tissue Sarcomas Iovance Biotherapeutics has reported positive early results from a clinical trial of lifileucel, a TIL therapy for advanced soft tissue sarcomas. The therapy demonstrated a 50% overall response rate in patients resistant to prior treatments, highlighting its potential to address significant unmet medical needs.
February 24, 2026 Iovance Biotherapeutics Reports Robust Growth in Q4 2025 and Full Year Results Iovance Biotherapeutics reported robust financial growth in Q4 2025, with a 30% revenue increase driven by its leading product, Amtagvi. The company is well-positioned for future success with ongoing clinical trials and global expansion plans.
February 24, 2026 Iovance Biotherapeutics Inc. Reports Strong Growth in 2025 Annual Report Iovance Biotherapeutics Inc. reported a 61% revenue increase to $263.5 million in 2025, primarily due to the success of Amtagvi®. While facing challenges with rising costs and a net loss, the company plans to expand its TIL therapy platform and enter international markets.
February 20, 2026 Iovance Biotherapeutics Announces Inducement Grants Under NASDAQ Listing Rule Iovance Biotherapeutics has granted inducement stock options to two new employees, aligning with its goal to innovate in cancer therapies. The grants are part of a strategic plan to attract talent and support the company's growth in TIL therapies.
February 11, 2026 Iovance Biotherapeutics Announces Upcoming Financial Results and Corporate Updates Iovance Biotherapeutics is set to announce its fourth quarter and full year financial results for 2025 on February 24, 2026. The conference call will provide crucial insights into the company's financial health and advancements in cancer treatment. Stakeholders are eagerly awaiting updates on key performance indicators and future strategies.
February 05, 2026 Iovance Biotherapeutics Reports Best-in-Class Real-World Data for Amtagvi® in Advanced Melanoma Iovance Biotherapeutics has released compelling real-world data for Amtagvi®, showing a 44% objective response rate in advanced melanoma patients. The findings suggest earlier treatment enhances efficacy, positioning Amtagvi as a leading therapy in this field. Ongoing clinical trials aim to further validate these promising results.
January 16, 2026 Iovance Biotherapeutics Announces Inducement Stock Options Grant Iovance Biotherapeutics has granted 97,710 stock options to 17 new employees as part of its strategy to attract talent. These options are part of the company’s commitment to innovative cancer therapies, including its FDA-approved TIL treatment. This move aims to enhance its workforce and drive future growth.
December 19, 2025 Iovance Biotherapeutics Inc. Announces Inducement Stock Options Grant Iovance Biotherapeutics announced the granting of stock options to four new non-executive employees as part of its inducement plan. This strategic move aims to attract and retain talent while aligning employee interests with the company's long-term goals in cancer therapy innovation.
November 21, 2025 Iovance Biotherapeutics Reports Inducement Grants to New Employees Iovance Biotherapeutics has approved inducement grants covering 164,900 shares for 11 new employees to enhance its workforce in cancer therapies. The grants follow regulatory compliance and are tied to a strategic vesting schedule, reflecting Iovance's commitment to innovation in the biotech sector.
November 06, 2025 Iovance Biotherapeutics Reports Strong Q3 2025 Results and Significant Pipeline Developments Iovance Biotherapeutics reported a robust financial performance in Q3 2025, with a 13% revenue increase and improved gross margins. The company is making strides with its flagship therapy, Amtagvi, and advancing its clinical pipeline, signaling significant growth potential in oncology.
November 06, 2025 Iovance Biotherapeutics Inc. Reports Significant Developments in 2025 Q3 Financials Iovance Biotherapeutics reported a 15% revenue increase in Q3 2025, driven by the launch of Amtagvi®, its FDA-approved TIL therapy. Despite a net loss, strategic restructuring aims to optimize operations and enhance market presence.
November 03, 2025 Iovance Biotherapeutics Reports Promising Interim Data for Lifileucel in Advanced Lung Cancer Iovance Biotherapeutics reports interim findings from the IOV-LUN-202 trial, showing lifileucel achieves a 25.6% objective response rate in advanced lung cancer. With a high disease control rate and favorable safety profile, the treatment could become a leading option for this patient population.
October 23, 2025 Iovance Biotherapeutics Prepares for Q3 2025 Financial Results Announcement Iovance Biotherapeutics is set to announce its Q3 2025 financial results on November 6, 2025. The company is a leader in cancer therapies, notably with its FDA-approved T cell therapy. The upcoming webcast will provide insights into the company’s performance and strategic direction.
October 17, 2025 Iovance Biotherapeutics Announces Inducement Grants for New Employees Iovance Biotherapeutics has approved inducement grants of stock options to nine new employees as part of its strategy to enhance its workforce. These grants are part of the company's commitment to innovation in TIL therapies for cancer treatment and its goal to lead in biotherapeutics.
August 07, 2025 Iovance Biotherapeutics Inc. Reports Q2 2025 Financial Results: A Transformative Period Amid Challenges and Growth Iovance Biotherapeutics Inc. has reported its Q2 2025 financial results, showcasing significant revenue growth driven by the launch of Amtagvi® for melanoma treatment. However, the company faces challenges with increased operational costs and a strategic workforce reduction aimed at optimizing its financial position.
May 08, 2025 Iovance Biotherapeutics Inc. Reports Robust Q1 2025 Financial Results Amidst Major Product Launch Iovance Biotherapeutics reported significant Q1 2025 financial results, highlighting a revenue increase of $48.6 million due to its product launch, Amtagvi®. Despite a net loss, the company's strategic outlook remains positive as it expands its TIL therapy pipeline.
March 21, 2025 Iovance Biotherapeutics Announces Inducement Grants to New Employees Iovance Biotherapeutics granted inducement stock options to 43 new employees to strengthen its workforce. This move supports the company's mission to lead in cancer treatment with innovative TIL therapies. The strategic hiring and employee retention initiatives highlight Iovance's commitment to growth and patient care.
February 27, 2025 Iovance Biotherapeutics Inc. Reports Remarkable Growth in 2024 Annual Report Iovance Biotherapeutics reported a staggering 13,698% revenue increase in 2024, driven by the launch of Amtagvi for melanoma. Despite net losses, the company shows strong market potential with ongoing innovations in TIL therapies.
February 27, 2025 Iovance Biotherapeutics Reports Robust Growth and Strategic Expansion in 2024 Iovance Biotherapeutics showcased impressive growth in 2024, with total product revenue reaching $164.1 million. The company aims to expand its market presence and enhance the adoption of its therapies, particularly Amtagvi, while pursuing international regulatory approvals.
February 21, 2025 Iovance Biotherapeutics Grants Inducement Stock Options to New Employees Iovance Biotherapeutics has granted inducement stock options for 328,730 shares to 71 new employees, reflecting its commitment to talent acquisition and employee retention. The options come with a structured vesting schedule and support the company's ongoing innovation in TIL therapies for cancer treatment.
February 19, 2025 SWOT Analysis of Iovance Biotherapeutics Inc in 2025 The SWOT analysis of Iovance Biotherapeutics Inc in 2025 highlights its strong position in cancer treatment through innovative TIL therapies, while also addressing financial challenges and competitive threats. The company has significant growth opportunities but must navigate regulatory hurdles and market acceptance risks.
February 18, 2025 Iovance Biotherapeutics Inc. Set to Release Financial Results and Corporate Updates Iovance Biotherapeutics is set to announce its Q4 and full year 2024 financial results on February 27, 2025. The report will be shared via a live webcast, followed by participation in major healthcare conferences. The company is focused on innovative cancer therapies, including its FDA-approved TIL product.
February 12, 2025 Iovance Biotherapeutics Announces Inducement Grants for New Chief Commercial Officer Iovance Biotherapeutics has appointed Daniel Kirby as Chief Commercial Officer, granting him stock options and restricted stock units to strengthen its leadership. This move is part of the company's strategy to enhance its marketing and sales as it innovates in cancer therapies.
February 10, 2025 Iovance Biotherapeutics Welcomes Dan Kirby as Chief Commercial Officer Iovance Biotherapeutics announces the appointment of Dan Kirby as Chief Commercial Officer, focusing on the U.S. launch of Amtagvi and market expansion. Kirby brings extensive biotech experience, aiming to enhance the company’s commercial strategy and growth.
November 07, 2024 Iovance Biotherapeutics Inc. Reports Q3 2024 Financial Results: A Transformative Period for Cancer Therapy Iovance Biotherapeutics Inc. reported a remarkable revenue increase in Q3 2024, largely due to the successful launch of Amtagvi for melanoma treatment. Despite a net loss and rising costs, the company is well-positioned for future growth with strong market demands and ongoing R&D investments.
August 08, 2024 Iovance Biotherapeutics Inc. Reports Remarkable Growth in Q2 2024 Iovance Biotherapeutics Inc. achieved a staggering 12,970% revenue growth in Q2 2024, primarily due to the successful launch of its cancer therapy Amtagvi™. Despite a net loss, the company's strong cash reserves and ongoing R&D investments indicate a bright future in cancer immunotherapy.
May 09, 2024 Iovance Biotherapeutics Inc. Reports 2024 Q1 Results: A New Era in Cancer Treatment Iovance Biotherapeutics Inc. reported Q1 2024 results, highlighting the launch of its first TIL cell therapy, Amtagvi. Despite a net loss, the company is optimistic about future revenues from Amtagvi and Proleukin as it continues to expand its R&D efforts and manufacturing capabilities.